Uwe Christians

Author PubWeight™ 89.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006 2.83
2 Concern Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest 2012 2.23
3 Early effect of tidal volume on lung injury biomarkers in surgical patients with healthy lungs. Anesthesiology 2014 2.06
4 Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology 2006 2.04
5 Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 2009 1.26
6 HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin Chem 2007 1.22
7 Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004 1.19
8 Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005 1.10
9 Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. Cancer Res 2009 1.09
10 Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal Biochem 2007 1.09
11 Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 2009 1.04
12 Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. JPEN J Parenter Enteral Nutr 2003 1.01
13 Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells. Pharm Res 2002 1.00
14 Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 2010 1.00
15 CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 2003 0.99
16 Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. Cardiovasc Res 2012 0.99
17 Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 2013 0.99
18 Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 2008 0.98
19 Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet 2003 0.97
20 Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol (1985) 2005 0.95
21 Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron Exp Nephrol 2009 0.94
22 A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011 0.92
23 Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv 2010 0.91
24 Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared. Rapid Commun Mass Spectrom 2011 0.90
25 Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther 2011 0.90
26 Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol 2009 0.90
27 Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res 2010 0.90
28 Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics 2007 0.89
29 Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res Hum Genet 2010 0.89
30 Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit 2005 0.89
31 Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007 0.88
32 Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention 2013 0.88
33 Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol 2010 0.87
34 Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther 2002 0.87
35 Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Analg 2009 0.87
36 Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.87
37 Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit 2016 0.86
38 Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom 2007 0.86
39 Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT. Transpl Int 2004 0.85
40 Proteomics and metabolomics in renal transplantation-quo vadis? Transpl Int 2012 0.85
41 Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit 2004 0.85
42 Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009 0.85
43 The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Xenotransplantation 2005 0.84
44 Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Investig Drugs 2003 0.84
45 The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv 2008 0.84
46 Identification and characterization of a bacterial cytochrome P450 for the metabolism of diclofenac. Appl Microbiol Biotechnol 2009 0.83
47 Enhanced leukocyte HIF-1alpha and HIF-1 DNA binding in humans after rapid ascent to 4300 m. Free Radic Biol Med 2009 0.83
48 Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study. Int J Cancer 2011 0.83
49 Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab 2002 0.82
50 Fibronectin-integrin signaling is required for L-glutamine's protection against gut injury. PLoS One 2012 0.82
51 Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol 2010 0.82
52 Cyclosporine can increase isoflurane MAC. Anesth Analg 2002 0.82
53 CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J Am Soc Nephrol 2013 0.82
54 Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant 2007 0.82
55 Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Release 2005 0.82
56 A metabonomic and proteomic analysis of changes in IMCD3 cells chronically adapted to hypertonicity. Nephron Physiol 2008 0.82
57 Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol 2013 0.81
58 Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation 2003 0.81
59 Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. Clin Chem 2010 0.81
60 Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica 2013 0.81
61 Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet 2013 0.81
62 A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer 2012 0.81
63 An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008 0.81
64 Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLoS One 2012 0.81
65 Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005 0.81
66 Liquid chromatography and mass spectrometry in food allergen detection. J Food Prot 2011 0.81
67 Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol 2011 0.81
68 A low blood volume LC-MS/MS assay for the quantification of fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children. J Sep Sci 2011 0.81
69 Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013 0.80
70 Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos 2013 0.80
71 Development and validation of an LC-MS/MS assay for the quantification of the trans-methylation pathway intermediates S-adenosylmethionine and S-adenosylhomocysteine in human plasma. Clin Chim Acta 2013 0.80
72 Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed Chromatogr 2009 0.80
73 Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101. Drug Metab Dispos 2008 0.79
74 Characterization of potential allergens in fenugreek (Trigonella foenum-graecum) using patient sera and MS-based proteomic analysis. J Proteomics 2010 0.79
75 Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res 2010 0.79
76 Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005 0.79
77 Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 2015 0.79
78 Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 2005 0.79
79 Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit 2007 0.79
80 Comparison of the quantification of acetaminophen in plasma, cerebrospinal fluid and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2013 0.79
81 Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit 2007 0.78
82 Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns. J Mass Spectrom 2011 0.78
83 Early increase in alveolar macrophage prostaglandin 15d-PGJ2 precedes neutrophil recruitment into lungs of cytokine-insufflated rats. Inflammation 2013 0.78
84 Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology 2010 0.78
85 Impact of organ preservation using HTK for graft flush and subsequent storage in UW in rat kidney transplantation. Eur Surg Res 2006 0.78
86 Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. Pediatrics 2006 0.77
87 Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit 2015 0.77
88 Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. Anesth Analg 2011 0.77
89 Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant 2008 0.76
90 Neurobehavioural activation during peripheral immunosuppression. Int J Neuropsychopharmacol 2012 0.76
91 Fatty acid desaturation index in human plasma: comparison of different analytical methodologies for the evaluation of diet effects. Anal Bioanal Chem 2014 0.76
92 A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 2011 0.76
93 MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms. Expert Opin Investig Drugs 2012 0.76
94 Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. Pediatr Nephrol 2006 0.75
95 Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). High Alt Med Biol 2006 0.75
96 Genetic and structure-function studies of missense mutations in human endothelial lipase. PLoS One 2013 0.75
97 Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study. Ther Drug Monit 2015 0.75
98 Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. Ther Drug Monit 2016 0.75
99 Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest 2017 0.75
100 Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. Ther Drug Monit 2016 0.75
101 Roger Jelliffe MD, FCP, FAAPS Obituary. Ther Drug Monit 2020 0.75
102 Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. J Clin Pharmacol 2010 0.75
103 A High-throughput HPLC-MS/MS Assay for the Detection, Quantification, and Simultaneous Structural Confirmation of 136 Drugs and Metabolites in Human Urine. Ther Drug Monit 2017 0.75
104 Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same! Pediatr Transplant 2006 0.75
105 An Atmospheric Pressure Ionization MS/MS Assay using Online Extraction for the Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine. Ther Drug Monit 2017 0.75